Drug intelligence / Profile preview

tetrahydrocannabinolic acid

Development stage
Unknown
Modality
Small Molecules
Administration
Inhalation, Oral, Sublingual, Buccal, Rectal, Topical, Transdermal, Intravenous, Intranasal, Ophthalmic
01

Overview

Tetrahydrocannabinolic acid (THCA) is a non-psychoactive cannabinoid and the acidic precursor to tetrahydrocannabinol (THC), found abundantly in raw and live cannabis plants. It converts to THC through a process called decarboxylation, typically induced by heat. THCA is being investigated for potential therapeutic properties, including anti-inflammatory, neuroprotective, and antiemetic effects, without producing the intoxicating effects associated with THC.

02

Targets

Anandamide reuptake transporterCNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DAGLA (Diacylglycerol lipase alpha)FAAHMGL (Methionine gamma-lyase)NAAA (N-acylethanolamine-hydrolyzing acid amidase)PC-PLC (Phosphatidylcholine-specific phospholipase C)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)TRPV3 (Transient receptor potential vanilloid subtype 3)TRPV4 (Transient receptor potential cation channel subfamily V member 4)

Beyond the preview

Go deeper on tetrahydrocannabinolic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetrahydrocannabinolic acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call